Beam Therapeutics is reaffirmed as a long-term buy due to its leadership in gene editing, particularly with its AATD treatment BEAM-302, expected to drive significant growth around 2028-2029. While the blockbuster potential of Risto-cel has been downgraded, Beam's first-mover advantage in base editing and potential AI partnerships support its future prospects. The company has a cash runway of 2-3 years but may face dilution before generating meaningful revenue. Overall, its valuation is fair compared to peers given the pipeline risks and innovation potential.
Beam Therapeutics is the subject of this update, with Pluang providing relevant market data for context. As of Sep 29, 2026 18:14 WIB, 44 of 100 priced Health-sector US stocks on Pluang rose while 49 fell. Notable movers include AZN at USD 168.27 with a 1-day change of +1.28%, AMLX at USD 29.50 down 1.17%, and INCY at USD 126.20 up 1.11%.
Bitcoin's probability of reaching $100,000 in 2026 rose sharply from 17% to 43% in mid-September but has since cooled to around 34% amid recent price declines below $83,000. This shift reflects changing market sentiment influenced by geopolitical ten...
Cullinan Therapeutics (CGEM) recently saw a stock price pullback, which is viewed as a good entry point before upcoming clinical updates scheduled for December 2026. The company is developing targeted treatments for cancer and autoimmune diseases, wi...
Nord Precious Metals Mining Inc. welcomes the Canadian government's proposed Productivity Mega Deduction, which could allow immediate 100% tax deductions on qualifying equipment investments. This proposal supports Nord's ongoing engineering and permi...
Raydium, Solana's largest decentralized exchange, recorded its highest weekly revenue since mid-2025, driven by the integration of StonkFun's tokenized stock platform. This integration cut token launch costs by nearly 90%, sparking a surge in trading...
Gold prices fell 4% to their lowest since early August as 10-year and 30-year Treasury yields rose above 5.3% and 5.4%, respectively. High-yield corporate bonds also declined, hitting their lowest since April 2025. Options traders are optimistic abou...
